Insider Trading (SEC Form 4)


Insiders are officers, directors, or significant investors. This page shows recent insider transactions for Drugs.

Transaction
Date
CompanyInsider Code
(see below)
Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2019-12-29 LPTN H.I.G. Ventures - Endosurgery, LLC (10% Owner) J 1,451,185 1,451,185
2019-12-29 LPTN Remeditex Ventures LLC (10% Owner) J 1,309,392 1,309,392
2018-02-23 ZTS Trawicki Roman (Executive Vice President) M 23,885 23,885 42.73 1,020,606
2018-02-23 EDGE Leuthner Brian A (President and CEO, Director) S -2,500 460,858 -0.54 15.37 -38,425 7,083,387 -0.54
2018-02-23 ZTS Trawicki Roman (Executive Vice President) S -23,885 0 -100.00 82 -1,958,570
2018-02-22 XNCR Foster Paul A (Chief Medical Officer) M 10,000 12,419 413.39 0.59 5,900
2018-02-22 HALO LEONHARDT HARRY J (SVP, GC and CCO) M 11,392 38,999 41.26
2018-02-22 HALO Stelzer Laurie (SVP, Chief Financial Officer) M 11,392 61,449 22.76
2018-02-22 HALO Torley Helen (President and CEO, Director) M 39,354 348,997 12.71
2018-02-22 HALO LEONHARDT HARRY J (SVP, GC and CCO) F -3,939 35,060 -10.10 19.28 -75,944
2018-02-22 HALO Stelzer Laurie (SVP, Chief Financial Officer) F -3,939 57,510 -6.41 19.28 -75,944
2018-02-22 HALO Torley Helen (President and CEO, Director) F -19,511 329,486 -5.59 19.28 -376,172
2018-02-22 PFE CANGIALOSI LORETTA V (Sr. Vice President, Controller) A 4,166 90,055 4.85
2018-02-22 ATRA Ciechanover Isaac E. (Chief Executive Officer, Director) S -1,400 1,037,691 -0.13 45.00 -63,000 46,696,095 -0.13
2018-02-22 ATRA Ciechanover Isaac E. (Chief Executive Officer, Director) S -1,600 1,039,091 -0.15 44.03 -70,448 45,751,177 -0.15
2018-02-22 ATRA Ciechanover Isaac E. (Chief Executive Officer, Director) S -1,600 1,040,691 -0.15 42.74 -68,384 44,479,133 -0.15
2018-02-22 EDGE Macdonald R. Loch (Chief Scientific Officer, Director) S -2,500 583,102 -0.43 14.49 -36,225 8,449,148 -0.43
2018-02-22 IDXX END WILLIAM T (Director) S -4,000 41,256 -8.84 184.4847 -737,939 7,611,101 -9.70
2018-02-22 EDGE Leuthner Brian A (President and CEO, Director) S -2,500 463,358 -0.54 15.47 -38,675 7,168,148 -0.54
2018-02-22 AMAR CHEN STEPHEN T (President, CEO & Chairman, Director, 10% Owner) P 2,500 4,320,741 0.06 0.28 700 1,209,807 0.06
2018-02-22 AMAR CHEN STEPHEN T (President, CEO & Chairman, Director, 10% Owner) P 2,500 4,323,241 0.06 0.27 675 1,167,275 0.06
2018-02-22 CLVS SPICKSCHEN THORLEF (Director) S -4,500 16,618 -21.31 60.00 -270,000 997,080 -27.08
2018-02-22 ZTS Bernal Alejandro (Executive Vice President) S -9,454 6,310 -59.97 81 -765,774 511,110 -149.83
2018-02-22 XNCR Foster Paul A (Chief Medical Officer) S -10,000 2,419 -80.52 26.03 -260,300 62,967 -413.39
2018-02-22 CLSN Martinez Alberto R Jr (Director) P 7,143 20,000 55.56 2.17 15,500 43,400 35.72
2018-02-21 NEOG HERBERT JAMES L (Executive Chairman, Director) M 18,669 1,169,595 1.62 40.4625 755,394
2018-02-21 HZNP DesJardin Michael A. (EVP, Technical Operations) M 2,181 6,269 53.35
2018-02-21 NEOG Quinlan Steven J. (VP & CFO) M 2,000 15,470 14.85 29.7075 59,415
2018-02-21 CYAN Cysewski Gerald R (CSO, Director) M 2,000 115,902 1.76 1.60 3,200
2018-02-21 ZTS Lagano Roxanne (Executive Vice President) M 35,663 49,919 250.16 26 927,238
2018-02-21 ZTS PECK KRISTIN C (Executive Vice President) M 32,000 67,530 90.06 26 832,000
2018-02-21 ARRY VAN LUNSEN GIL J (Director) M 13,500 32,797 69.96 2.46 33,210
2018-02-21 ARRY VAN LUNSEN GIL J (Director) M 8,000 40,797 24.39 3.37 26,960
2018-02-21 ZTS Bernal Alejandro (Executive Vice President) M 32,097 47,861 203.61 26 834,522
2018-02-21 ZTS Bernal Alejandro (Executive Vice President) M 28,089 75,950 58.69 30.89 867,669
2018-02-21 KBPH COMINDUS FINANCE CORP. (10% Owner) BENARROCH GEORGES (President, Director) J 958,752 2,697,085 55.15 1.13 1,083,390
2018-02-21 KBPH COMINDUS FINANCE CORP. (10% Owner) BENARROCH GEORGES (President, Director) J -958,752 2,697,085 -26.23 1.13 -1,083,390
2018-02-21 GILD Meyers James R (EVP Worldwide Commercial Ops) G -2,323 5,393 -30.11
2018-02-21 GILD Meyers James R (EVP Worldwide Commercial Ops) G 2,323 132,083 1.79
2018-02-21 GILD BISCHOFBERGER NORBERT W (EVP, R&D and CSO) G -9,393 19,602 -32.40
2018-02-21 GILD BISCHOFBERGER NORBERT W (EVP, R&D and CSO) G 9,393 2,317,800 0.41
2018-02-21 ENDP Pera Antonio R (President, Par Pharmaceutical) F -3,117 24,203 -11.41 6.72 -20,946
2018-02-21 ENDP Maletta Matthew Joseph (EVP, Chief Legal Officer) F -3,507 15,049 -18.90 6.72 -23,567
2018-02-21 ENDP Coughlin Terrance J (EVP, Chief Operating Officer) F -6,816 155,246 -4.21 6.72 -45,804
2018-02-21 ENDP Coleman Blaise (EVP, Chief Financial Officer) F -3,595 21,191 -14.50 6.72 -24,158
2018-02-21 ENDP Campanelli Paul (President, CEO, Director) F -24,184 267,763 -8.28 6.72 -162,516
2018-02-21 ENDP Rudio Daniel (SVP, Controller) F -1,301 9,242 -12.34 6.72 -8,743
2018-02-21 HZNP DesJardin Michael A. (EVP, Technical Operations) F -891 5,378 -14.21 14.09 -12,554
2018-02-21 GILD Meyers James R (EVP Worldwide Commercial Ops) F -1,647 7,716 -17.59 80.69 -132,896
2018-02-21 GILD BISCHOFBERGER NORBERT W (EVP, R&D and CSO) F -7,071 28,995 -19.61 80.69 -570,559
A
Grant, award, or other acquisition of securities from the company (such as an option)
K
Equity swaps and similar hedging transactions
P
Purchase of securities on an exchange or from another person
S
Sale of securities on an exchange or to another person
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
M
Exercise or conversion of derivative security received from the company (such as an option)
G
Gift of securities by or to the insider
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)